Figure 4From: Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximab Kaplan-Meier curves for median overall survival (OS) of colorectal cancer patients treated with irinotecan and cetuximab showing phosphorylated MAPK expression (-------) and without phosphorylated MAPK expression (———) in either primary tumours (A, 11.2 months vs. 26.2 months, p = 0.1) or metastases (B, 7.8 months vs. 26 months, p = 0.0004). Back to article page